These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22261458)

  • 1. Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens.
    Zhao L; Guo M; Sneige N; Gong Y
    Am J Clin Pathol; 2012 Feb; 137(2):304-9. PubMed ID: 22261458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
    McKnight R; Cohen C; Siddiqui MT
    Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
    Liliac L; Carcangiu ML; Canevari S; Căruntu ID; Ciobanu Apostol DG; Danciu M; Onofriescu M; Amălinei C
    Rom J Morphol Embryol; 2013; 54(1):17-27. PubMed ID: 23529305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.
    Laury AR; Hornick JL; Perets R; Krane JF; Corson J; Drapkin R; Hirsch MS
    Am J Surg Pathol; 2010 May; 34(5):627-35. PubMed ID: 20414098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
    Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
    Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serous carcinoma of the ovary with squamous differentiation: a case report and a literature review.
    Roberts DE; Lombard CM
    Int J Gynecol Pathol; 2013 Sep; 32(5):459-63. PubMed ID: 23896710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
    Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
    APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
    Nonaka D; Chiriboga L; Soslow RA
    Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy.
    Wang Y; Wang Y; Li J; Yuan Z; Yuan B; Zhang T; Cragun JM; Kong B; Zheng W
    J Hematol Oncol; 2013 Aug; 6():60. PubMed ID: 23958394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
    Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer.
    Rhodes A; Vallikkannu N; Jayalakshmi P
    Br J Biomed Sci; 2017 Apr; 74(2):65-70. PubMed ID: 28367736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology.
    Bansal A; Srinivasan R; Rohilla M; Sundaram A; Rai B; Rajwanshi A; Suri V; Saha SC; Gupta N; Gupta P; Dey P
    Am J Clin Pathol; 2020 Jun; 154(1):103-114. PubMed ID: 32271370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
    Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
    Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusions.
    Wiseman W; Michael CW; Roh MH
    Diagn Cytopathol; 2011 Sep; 39(9):651-6. PubMed ID: 20949455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon.
    Boyd C; McCluggage WG
    Am J Surg Pathol; 2012 Mar; 36(3):368-75. PubMed ID: 22082603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors.
    Wang M; Ma H; Pan Y; Xiao W; Li J; Yu J; He J
    Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):280-7. PubMed ID: 24992169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinosarcoma arising from high-grade serous carcinoma of the ovary without estrogen receptor, WT-1, and PAX8 immunoreactivity.
    Harada N; Nobuhara I; Haruta N; Higashiura Y; Fujii H; Yamao K; Shimada K
    Taiwan J Obstet Gynecol; 2022 Jan; 61(1):110-114. PubMed ID: 35181017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Ovarian Serous Carcinoma of the Breast.
    Akturk G; Guray Durak M; Cakir Y; Koyuncuoglu M; Sevinc AI; Canda T
    Breast J; 2017 May; 23(3):362-364. PubMed ID: 27943469
    [No Abstract]   [Full Text] [Related]  

  • 19. PAX8, auseful biomarker for ovarianserous tumors.
    Lin X; Wu BB; Xing YQ; Wang DS; Li J
    Hum Pathol; 2016 May; 51():146. PubMed ID: 26980044
    [No Abstract]   [Full Text] [Related]  

  • 20. Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens.
    Ren S; Klump W
    Arch Pathol Lab Med; 2019 Jun; 143(6):677-682. PubMed ID: 29688031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.